Preserving fertility in patients undergoing treatment for breast cancer: Current perspectives

Breast Cancer: Targets and Therapy

Volumn 6, Issue , 2014, Pages 93-101

  Moffat, Rebecca ^a   Güth, Uwe ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

Author keywords

Breast cancer; Chemotherapy; Fertility preservation; Oncofertility

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; CHORIONIC GONADOTROPIN; DNA TOPOISOMERASE INHIBITOR; GONADORELIN; MUELLERIAN INHIBITING FACTOR; TAXANE DERIVATIVE; FOLLITROPIN;

AGE; AMENORRHEA; ATTITUDE; BIRTH RATE; BREAST CANCER; CONCEPTION; CRYOPRESERVATION; DISEASE CONTROL; EMBRYO; FERTILITY PRESERVATION; FERTILIZATION IN VITRO; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; HEALTH CARE PERSONNEL; HUMAN; INFERTILITY THERAPY; LAPAROTOMY; MENOPAUSE; OOCYTE; OOCYTE MATURATION; OVARY FOLLICLE; OVARY FUNCTION; PREGNANCY; QUALITY OF LIFE; REVIEW; SOCIAL PSYCHOLOGY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; FEMALE FERTILITY; INFERTILITY; KNOWLEDGE; LAPAROSCOPY; OVARIAN RESERVE; OVULATION; OVULATION INHIBITION; TRANSVAGINAL ECHOGRAPHY;

EID: 84904672276     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S47234     Document Type: Review

References (102)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Bland KI, Menck HR, Scott-Conner CE, Morrow M, Winchester DJ, Winchester DP. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998;83(6):1262-1273.
3. Martin J, Hamilton B, Ventura S, et al. Births: Final data for 2009. National vital statistics reports. Hyattsville, MD: National Center for Health Statistics; 2011. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_01.pdf. Accessed May 30, 2014.
4. Martinez GM, Chandra A, Abma JC, Jones J, Mosher WD. Fertility, contraception, and fatherhood: data on men and women from cycle 6 (2002) of the 2002 National Survey of Family Growth. Vital Health Stat. 2006;26:1-142.
5. Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer. 1999;86(4):697-709.
6. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Stat Facts Sheets: Breast cancer. Available from: http://seer.cancer.gov/statfacts/html/breast.html. Accessed May 30, 2014.
7. Canada AL, Schover LR. The psychosocial impact of interrupted childbearing in long-term female cancer survivors. Psychooncology. 2012;21(2):134-143.
8. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83(6):1622-1628.
9. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917-2931.
10. Adams E, Hill E, Watson E. Fertility preservation in cancer survivors: a national survey of oncologists' current knowledge, practice and attitudes. Br J Cancer. 2013;108(8):1602-1615.
11. Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M. Fertility preservation in. 1,000 patients: patient's characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet. 2011;283(3):651-656.
12. Quinn G, Vadaparampil S, Jacobsen P, et al. National survey of physician practice patterns: fertility preservation and cancer patients. J Clin Oncol. 2009;27(35):5952-5957.
13. Mueller BA, Simon MS, Deapen D, Kamineni A, Malone KE, Daling JR. Childbearing and survival after breast carcinoma in young women. Cancer. 2003;98(6):1131-1140.
14. Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47(1):74-83.
15. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect". Am J Obstet Gynecol. 1994;170(3):818-823.
16. Largillier R, Savignoni A, Gligorov J, et al. Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged, 35 years: a GET(N)A Working Group analysis. Cancer. 2009;115(22):5155-5165.
17. United States. Fertility Clinic Success Rate and Certification Act of 1992: Public Law 102-493. US Statut Large. 1992;106:3146-3152.
18. Committee on Gynecologic Practice of American College of Obstetricians and Gynecologists; Practice Committee of American Society for Reproductive Medicine. Age-related fertility decline: a committee opinion. Fertil Steril. 2008;90(Suppl 5):S154-S155.
19. Tarlatzis BC, Zepiridis L. Perimenopausal conception. Ann N Y Acad Sci. 2003;997:93-104.
20. Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2011 Assisted Reproductive Technology Fertility Clinic Success Rates Report. Atlanta, GA, USA: US Dept of Health and Human Services; 2013. Available from: http://www.cdc.gov/art/ART2011/PDFs/ART_2011_Clinic_Report-Full.pdf. Accessed May 31, 2014.
21. MacDougall K, Beyene Y, Nachtigall RD. Age shock: misperceptions of the impact of age on fertility before and after IVF in women who conceived after age 40. Hum Reprod. 2013;28(2):350-356.
22. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10):1342-1346.
23. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2012;98(6):1407-1415.
24. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685-718.
25. Streuli I, Fraisse T, Chapron C, Bijaoui G, Bischof P, de Ziegler D. Clinical uses of anti-Mullerian hormone assays: pitfalls and promises. Fertil Steril. 2009;91(1):226-230.
26. Rustamov O, Smith A, Roberts SA, et al. Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod. 2012;27(10):3085-3091.
27. Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer. 2013;49(16): 3404-3411.
28. Casadei L, Manicuti C, Puca F, Madrigale A, Emidi E, Piccione E. Can anti-Mullerian hormone be predictive of spontaneous onset of pregnancy in women with unexplained infertility? J Obstet Gynaecol. 2013;33(8):857-861.
29. Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26-36.
30. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-1729.
31. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045-1051.
32. Meirow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010;53(4):727-739.
33. Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary? Hum Reprod Update. 2012;18(5):525-535.
34. Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. Oncologist. 2012;17(11):1409-1417.
35. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11(5):422-434.
36. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-2223.
37. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (,35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13(2):273-279.
38. Lewis PE, Sheng M, Rhodes MM, Jackson KE, Schover LR. Psychosocial concerns of young African American breast cancer survivors. J Psychosoc Oncol. 2012;30(2):168-184.
39. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004; 22(20):4174-4183.
40. Schover LR. Patient attitudes toward fertility preservation. Pediatr Blood Cancer. 2009;53(2):281-284.
41. Letourneau JM, Ebbel EE, Katz PP, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710-1717.
42. Klemp JR, Kim SS. Fertility preservation in young women with breast cancer. J Assist Reprod Genet. 2012;29(6):469-472.
43. Tschudin S, Bitzer J. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum Reprod Update. 2009;15(5):587-597.
44. Garvelink MM, ter Kuile MM, Fischer MJ, et al. Development of a decision aid about fertility preservation for women with breast cancer in The Netherlands. J Psychosom Obstet Gynaecol. 2013;34(4):170-178.
45. Peate M, Meiser B, Cheah BC, et al. Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. Br J Cancer. 2012;106(6):1053-1061.
46. Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril. 2013;99(6):1496-1502.
47. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37-43.
48. [No authors listed]. ACOG: Committee Opinion No 584: oocyte cryopreservation. Obstet Gynecol. 2014;123(1):221-222.
49. Bedoschi G, Turan V, Oktay K. Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: is it protective? Curr Breast Cancer Rep. 2013;5(4):302-308.
50. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510.
51. Barcroft J, Dayoub N, Thong KJ. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. J Assist Reprod Genet. 2013;30(11):1407-1413.
52. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol. 2010;28(31):4683-4686.
53. Kim J, Kim KH, Mersereau JE. Building a successful fertility preservation program at a major cancer center. J Gynecol Oncol. 2014;25(2): 148-154.
54. Noyes N, Melzer K, Druckenmiller S, Fino ME, Smith M, Knopman JM. Experiences in fertility preservation: lessons learned to ensure that fertility and reproductive autonomy remain options for cancer survivors. J Assist Reprod Genet. 2013;30(10):1263-1270.
55. Sagi M, Weinberg N, Eilat A, et al. Preimplantation genetic diagnosis for BRCA1/2-a novel clinical experience. Prenat Diagn. 2009;29(5): 508-513.
56. Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013;100(5): 1214-1223.
57. Ayensu-Coker L, Essig E, Breech LL, Lindheim S. Ethical quandaries in gamete-embryo cryopreservation related to oncofertility. J Law Med Ethics. 2013;41(3):711-719.
58. Campo-Engelstein L. Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. J Clin Oncol. 2010;28(8):1284-1286.
59. Shah DK, Goldman E, Fisseha S. Medical, ethical, and legal considerations in fertility preservation. Int J Gynaecol Obstet. 2011;115(1):11-15.
60. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673-1680.
61. Sonmezer M, Turkcuoglu I, Coskun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011;95(6):2125. e9-e11.
62. Madrigrano A, Westphal L, Wapnir I. Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg. 2007;194(4): 477-481.
63. de Ziegler D, Streuli I, Vasilopoulos I, Decanter C, This P, Chapron C. Cancer and fecundity issues mandate a multidisciplinary approach. Fertil Steril. 2010;93(3):691-696.
64. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil Steril. 1996;66(1): 151-153.
65. Humaidan P, Kol S, Papanikolaou EG. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17(4):510-524.
66. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012;2:CD008605.
67. Mozes M, Bogokowsky H, Antebi E, et al. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet. 1965;2(7424):1213-1215.
68. Dahhan T, Balkenende E, van Wely M, Linn S, Goddijn M. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. Cochrane Database Syst Rev. 2013;11: CD010240.
69. Martinez-Burgos M, Herrero L, Megias D, et al. Vitrification versus slow freezing of oocytes: effects on morphologic appearance, meiotic spindle configuration, and DNA damage. Fertil Steril. 2011;95(1):374-377.
70. Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online. 2005;11(3):300-308.
71. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006;86(1):70-80.
72. Cil AP, Bang H, Oktay K. Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis. Fertil Steril. 2013;100(2):492-499. e3.
73. Domingo J, Guillen V, Ayllon Y, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97(4):930-934.
74. Kim SS, Donnez J, Barri P, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29(6):465-468.
75. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(9):3146-3154.
76. Donnez J, Dolmans MM, Pellicer A, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril. 2013;99(6):1503-1513.
77. Kim SS. Revisiting the role of heterotopic ovarian transplantation: futility or fertility. Reprod Biomed Online. 2014;28(2):141-145.
78. Oktay K. Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection? Hum Reprod. 2006;21(6):1345-1348.
79. Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009;33(8):1125-1136.
80. Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril. 2014;101(5):1237-1243.
81. Berwanger AL, Finet A, El Hachem H, Le Parco S, Hesters L, Grynberg M. New trends in female fertility preservation: in vitro maturation of oocytes. Future Oncol. 2012;8(12):1567-1573.
82. Huang JY, Tulandi T, Holzer H, Tan SL, Chian RC. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril. 2008;89(3):567-572.
83. Chian RC, Huang JY, Gilbert L, et al. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertil Steril. 2009; 91(6):2391-2398.
84. Ronn R, Holzer HE. Oncofertility in Canada: cryopreservation and alternative options for future parenthood. Curr Oncol. 2014;21(1):e137-e146.
85. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril. 2013;99(3):663-666.
86. Turner NH, Partridge A, Sanna G, Di Leo A, Biganzoli L. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol. 2013;24(9):2224-2235.
87. Partridge AH, Gelber S, Peppercorn J, et al. Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer. 2008;8(1):65-69.
88. Chandra A, Stephen EH. Infertility service use among US women: 1995 and 2002. Fertil Steril. 2010;93(3):725-736.
89. Moffat R, de Geyter C, Myrick ME, et al. Young women with breast cancer: how many are actually candidates for fertility preservation? Arch Gynecol Obstet. 2012;286(6):1521-1527.
90. Baxter NN, Sutradhar R, DelGuidice ME, et al. A population-based study of rates of childbirth in recurrence-free female young adult survivors of non-gynecologic malignancies. BMC Cancer. 2013;13:30.
91. Cvancarova M, Samuelsen SO, Magelssen H, Fossa SD. Reproduction rates after cancer treatment: experience from the Norwegian radium hospital. J Clin Oncol. 2009;27(3):334-343.
92. Goncalves V, Sehovic I, Quinn G. Childbearing attitudes and decisions of young breast cancer survivors: a systematic review. Hum Reprod Update. 2014;20(2):279-292.
93. Kellerman SE, Herold J. Physician response to surveys. A review of the literature. Am J Prev Med. 2001;20(1):61-67.
94. Shimizu C, Bando H, Kato T, Mizota Y, Yamamoto S, Fujiwara Y. Physicians' knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. Breast Cancer. 2013;20(3):230-240.
95. King JW, Davies MC, Roche N, Abraham JM, Jones AL. Fertility preservation in women undergoing treatment for breast cancer in the UK: a questionnaire study. Oncologist. 2012;17(7):910-916.
96. Shimizu C, Kato T, Tamura N, et al. Perception and needs of reproductive specialists with regard to fertility preservation of young breast cancer patients. Int J Clin Oncol. February 22, 2014. [Epub ahead of print.]
97. Goossens J, Delbaere I, Van Lancker A, Beeckman D, Verhaeghe S, Van Hecke A. Cancer patients' and professional caregivers' needs, preferences and factors associated with receiving and providing fertility-related information: a mixed-methods systematic review. Int J Nurs Stud. 2014;51(2):300-319.
98. Niemasik EE, Letourneau J, Dohan D, et al. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. J Cancer Surviv. 2012;6(3):324-332.
99. Yee S, Abrol K, McDonald M, Tonelli M, Liu KE. Addressing oncofertility needs: views of female cancer patients in fertility preservation. J Psychosoc Oncol. 2012;30(3):331-346.
100. Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151-1156.
101. Lee S, Heytens E, Moy F, Ozkavukcu S, Oktay K. Determinants of access to fertility preservation in women with breast cancer. Fertil Steril. 2011;95(6):1932-1936.
102. Letourneau JM, Smith JF, Ebbel EE, et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer. 2012;118(18):4579-4588.